Cabozantinib Versus Standard-of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell Carcinoma in Treatment-naïve Patients: a Systematic Review and Network Meta-Analysis

BACKGROUND: Cabozantinib has recently been evaluated as a first-line treatment in advanced renal cell carcinoma (aRCC). OBJECTIVE: To indirectly assess efficacy of cabozantinib versus standard-of-care (SoC) comparators in the first-line treatment of aRCC. METHODS: We conducted a systematic literatur...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Target Oncol
Hlavní autoři: Schmidt, Elvira, Lister, Johanna, Neumann, Monika, Wiecek, Witold, Fu, Shuai, Vataire, Anne-Lise, Sostar, Jelena, Huang, Shengnan, Marteau, Florence
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer International Publishing 2018
Témata:
Original Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5887000/
https://ncbi.nlm.nih.gov/pubmed/29492762
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-018-0559-0
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky